Seth Wander, MD, PhD, discusses the significance of ESR1 mutations in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Hormone therapies have played a major role in improving survival for patients with ER+ breast cancer [1]. By blocking or reducing estrogen’s impact, these treatments slow the cancer’s growth ...

That estrogen plays a critical role in bone health in women is a well-known fact. Deficiency of estrogen leads to increased bone loss, lower bone mineral density (BMD), and increased fracture risk.